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Objectives: To compare the clinical effectiveness of
the intravesical administration of combined hyaluronic
acid and chondroitin sulfate (HA+CS) versus current
standard management in adult women with recurrent
urinary tract infections (RUTIs).
Setting: A European Union-based multicentre,
retrospective nested case–control study.
Participants: 276 adult women treated for RUTIs
starting from 2009 to 2013.
Interventions: Patients treated with either intravesical
administration of HA+CS or standard of care
(antimicrobial/immunoactive prophylaxis/probiotics/
cranberry).
Primary and secondary outcome measures: The
primary outcome was occurrence of bacteriologically
confirmed recurrence within 12 months. Secondary
outcomes were time to recurrence, total number of
recurrences, health-related quality of life and healthcare
resource consumption. Crude and adjusted results for
unbalanced characteristics are presented.
Results: 181 patients treated with HA+CS and 95
patients treated with standard of care from 7 centres
were included. The crude and adjusted ORs (95% CI)
for the primary end point were 0.77 (0.46 to 1.28) and
0.51 (0.27 to 0.96), respectively. However, no evidence
of improvement in terms of total number of
recurrences (incidence rate ratio (95% CI), 0.99 (0.69
to 1.43)) or time to first recurrence was seen (HR
(95% CI), 0.99 (0.61 to 1.61)). The benefit of
intravesical HA+CS therapy improves when the number
of instillations is ≥5.
Conclusions: Our results show that bladder
instillations of combined HA+CS reduce the risk of
bacteriologically confirmed recurrences compared with
the current standard management of RUTIs. Total
incidence rates and hazard rates were instead non-
significantly different between the 2 groups after
adjusting for unbalanced factors. In contrast to what
happens with antibiotic prophylaxis, the effectiveness
of the HA+CS reinstatement therapy improves over
time.
Trial registration number: NCT02016118.
BACKGROUND
Urinary tract infection (UTI) is a major
healthcare concern in women with an annual
incidence of 30 per 1000.1 Nearly 33% of
women will have had at least one UTI episode,
with characteristics of acute cystitis, requiring
antimicrobial therapy by the age of 24 years
and as many as 60% of women reporting
having had a UTI in their lifetime.2 3
UTIs have a propensity to recur;4 5 evi-
dence shows that between 24% and 50% of
Strengths and limitations of this study
▪ These real-world data show that bladder instilla-
tions of combined hyaluronic acid and chondro-
itin sulfate may reduce the risk of
bacteriologically confirmed urinary tract infec-
tions versus current standard management.
▪ However, if the recurrence occurs, there is no
evidence of benefit in terms of total number or
time to first recurrence.
▪ The number of instillations seems to be an
important marker of success for this non-
antimicrobial therapy.
▪ Owing to the retrospective observational design,
these findings need confirmation from prospect-
ive and preferably randomised studies.
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initial episodes are followed by a second infection within
6 months.6–9 A widely accepted deﬁnition of recurrent
UTIs (RUTIs) is two or more UTI episodes over
6 months, or three or more episodes over 12 months.10
On a population scale, the high incidence and preva-
lence of RUTIs results in considerable healthcare costs;
at the individual level, the impact of this condition on
health-related quality of life (HRQoL) is not negli-
gible.11–13
The pathogenesis of RUTI involves colonisation of the
vagina with uropathogenic bacteria and subsequent
migration per urethra to the bladder. About 68–77% of
recurrences caused by Escherichia coli involve strains gen-
etically indistinguishable from those that caused previ-
ous infections.14
The diagnosis is often made on clinical presentation
with local genitourinary symptoms of dysuria, frequency,
and urgency or hesitancy appearing suddenly.14
However, urine culture is useful in women presenting
with RUTI to conﬁrm the diagnosis, direct antimicrobial
therapy and exclude infection from an overactive
bladder or interstitial cystitis.15 Evidence-based clinical
practice guidelines recommend empiric initial therapy
for acute management or continuous antimicrobial
therapy or self-initiated therapy and prophylaxis, either
antimicrobial or non-antimicrobial based.16 17
The choice of speciﬁc strategy for care depends on
the number of recurrences experienced per year, the
patient’s preferences and careful review of modiﬁable
risk factors.14 18 As the second most common reason for
prescribing antibiotics (following otitis media), there is
currently increasing concern about empiric use of these
agents due to increased antimicrobial resistance (AMR).
Antibiotic use selects for resistant pathogens: a major
risk factor for an antibioticresistant UTI is prior anti-
biotic use.5 In an international survey investigating the
prevalence and susceptibility of pathogens causing cyst-
itis, 10.3% of E. coli isolates were resistant to at least
three different classes of antimicrobial agents, including
ampicillin (48.3%), trimethoprim/sulfamethoxazole
(29.4%) and nalidixic acid (18.6%).19
Non-antimicrobial prevention strategies have become
popular in the age of increasing antimicrobial use and
resistance. However, no probiotic agent has been
approved for therapeutic use and the potential beneﬁt
of cranberry in terms of product type (solid vs liquid),
dosing and optimal patient population remains to be
elucidated.14 18 A new therapy based on the reinstate-
ment of the glycosaminoglycan (GAG) bladder epithe-
lium has recently been proposed for the treatment of
RUTIs.20 This GAG layer consists of non-sulfated, for
example, hyaluronic acid (HA), and sulfated, for
example, heparan sulfate and heparin, chondroitin
sulfate (CS), dermatan sulfate and keratan sulfate,
GAGs. Limited evidence has shown the preventive activ-
ity of intravesical GAG substation therapy (with HA
alone or with HA+CS) on recurrence of infections in
patients with recurrent bacterial cystitis.21 However,
large-scale studies are needed to underline the beneﬁt
of this therapy.22
Therefore, we decided to perform a European retro-
spective multicentre study to compare the clinical effect-
iveness of the intravesical administration of combined
HA+CS (ialuril, IBSA Institut Biochimique SA) versus




This was a European Union (EU) based multicentre,
retrospective nested case–control comparison of individ-
ual patient data collected from electronic medical
records and/or administrative databases available at the
participating institutions. Centres using the intravesical
administration of combined HA+CS, in the countries
where ialuril was already registered and on the market
(ialuril received a CE mark for this indication in 2009),
were identiﬁed and invited to take part in the study.
Study population
All patients treated with either HA+CS or standard of
care at the participating centres, high volume organisa-
tions with speciﬁc expertise in the treatment of UTIs,
starting from 2009, were included if they were women,
aged 18–75 years, diagnosed with RUTIs, deﬁned as at
least three episodes of uncomplicated UTIs accompan-
ied by clinical symptoms and documented by urine
culture with the isolation of >103 CFU/mL of an identi-
ﬁed pathogen in the past 12 months. Uncomplicated
UTI is deﬁned as an infection in a person with a normal
urinary tract and function.17 Women with complicated
UTIs (ie, individuals with functional or structural abnor-
malities of the genitourinary tract) were excluded.
Within Europe, patients at ﬁrst diagnosis of RUTIs are
offered an approach based on behavioural changes, anti-
microbial prophylaxis or aspeciﬁc non-antimicrobial pre-
vention. However, several women refuse to take
antimicrobials over an extended period of time; hence,
intravesical administration of HA+CS is intended for
women refractory or not satisﬁed with ﬁrst-line manage-
ment of RUTIs. On the basis of a previous cohort
study,11 we estimated that 208 patients were needed to
observe a 50% difference in the proportions of patients
recurring between the two groups within 12 months with
90% power and an α-level of 0.05.
Groups and interventions
Patients were treated with intravesical administration of
combined HA 1.6% and CS 2.0%. The recommended
scheme is one instillation per week for the ﬁrst month,
followed by one instillation every 2 weeks for the second
month and one instillation per month afterwards until
stable remission of the symptoms; however, different pat-
terns are seen in clinical practice. These patients were
compared with patients treated with antimicrobial
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prophylaxis (continuous or postcoital), or immunoactive
prophylaxis or prophylaxis with probiotics or prophylaxis
with cranberry, or a combination of these,17 as recom-
mended by the European Association of Urology.
Study outcomes
The primary outcome for this study was the occurrence
of objective UTI recurrence, deﬁned as the occurrence
of at least one bacteriologically conﬁrmed UTI within
12 months after treatment initiation for RUTIs.
According to current clinical guidelines, in non-
pregnant women, urine culture is recommended in
symptomatic patients only. Information about clinically
conﬁrmed recurrences was also sought, although they
are not reported in this manuscript as they are assumed
to be less objective than the bacteriologically conﬁrmed
ones. Patients who developed a UTI while on the
HA+CS instillation protocol were treated according to
clinical guidelines with antibiotics but could continue
the instillations afterwards. After the ﬁrst bacteriologic-
ally conﬁrmed recurrence, the time to ﬁrst recurrence
was recorded, as well as the number of additional UTIs.
The secondary outcome measures were the time to recur-
rence (deﬁned as the time from the start of the treatment
until the occurrence of the ﬁrst objective recurrence);
the total number of recurrences; HRQoL as assessed
through the Short Form 36 (SF-36)23 or Euro QoL 5D
(EQ-5D)24 questionnaires. Dutch,25 Italian26 and UK27
tariffs were used to estimate utility values from the EQ-5D
questionnaires in the Netherlands, Italy and Slovakia,
respectively. Information about healthcare resource con-
sumption was also collected. A cost analysis was planned
and will be the subject of a future publication.
Data collection
General patient demographic characteristics, diagnosis
and treatment information were collected on the basis
of a predeﬁned form designed on the input obtained
from collaborating centres during a workshop held in
July 2013. An intuitive electronic system was implemen-
ted (Advice Pharma Ltd) to record and store data on a
secure remote server provider.
Statistical analyses
Continuous baseline characteristics are presented as the
median and IQR or mean and SD, as appropriate. For
proportions, absolute and relative frequencies are
reported. The Wilcoxon-Mann-Whitney test or Student t
test was used for continuous and ordinal variables base-
line differences, whereas the χ2 test was used for propor-
tions. In our primary analyses, we applied logistic,
Poisson and Cox regression for objective recurrence,
number of recurrences and time to recurrence, respect-
ively. Results were presented as crude and adjusted OR,
incidence rate ratio (IRR) and HR, respectively, with
their 95% CIs. Adjusting variables were age, body mass
index (BMI), employment and menopause status, post-
coital infections, dyspareunia, Female Sexual Function
Index (FSFI) and severity of RUTI. A prespeciﬁed sensi-
tivity analysis was conducted to investigate the impact of
adherence to HA+CS treatment on clinical outcomes
considering patients who had ≥5 instillations. Pairwise
deletion was used to deal with missing data. All signiﬁ-
cance tests were two-tailed at the 0.05 signiﬁcance level.
All the analyses were conducted using Stata SE
StataCorp LP 11.
RESULTS
Overall, 276 patients treated for RUTIs at seven
European centres from January 2009 up to December
2013 were included in the analyses. Of these, 181
women were treated with HA+CS intravesical administra-
tion and 95 women received standard management of
RUTIs. The numerical imbalance was probably due to
the participating organisations being tertiary referral
centres for patients who are not satisﬁed with standard
management of RUTIs. A ﬂow diagram reporting the
number of patients at each stage of the study is shown in
ﬁgure 1. The baseline sociodemographic and clinical
characteristics of patients are reported in table 1. Given
the non-experimental nature of the study, the distribu-
tion of several characteristics was not homogeneous
between the two groups; in particular, women treated
with HA+CS were older, with a higher BMI and probabil-
ity of dyspareunia.
Primary analyses
In the HA+CS group, 55.7% of patients showed bacterio-
logically conﬁrmed recurrences, whereas 62.1% had such
recurrence in the standard of care group (p=0.313).
However, the adjusted OR (95% CI) for developing a bac-
teriologically conﬁrmed recurrence within 12 months was
0.51 (0.27 to 0.96), meaning that, other characteristics
being equal, there is a 49% reduced risk of developing a
recurrence in patients treated with HA+CS compared
with standard care (table 2). When the number of re-
currences is considered, in the HA+CS group there
were 121 bacteriologically conﬁrmed recurrences in 61.5
Figure 1 Flow diagram describing numbers of individuals at
each stage of study. HA+CS, hyaluronic acid and chondroitin
sulfate.
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person-years, whereas in the standard treatment group
there were 59 bacteriologically conﬁrmed recurrences in
51.1 person-years (p=0.001). However, we observed an
adjusted IRR (95% CI) of 0.99 (0.69 to 1.43), showing
non-signiﬁcant differences in the incidence rates
between the group treated with HA+CS and the control.
Similar results were obtained from the univariate and
multivariate Cox regression models used to estimate the
HR (95% CI) for the time to ﬁrst bacteriologically
conﬁrmed recurrence, with an unadjusted estimate of
0.99 (0.61 to 1.61) (table 2). Although the median time
to ﬁrst recurrence was higher in the standard care
group (169.5 days (IQR, 72.5–341.5) vs 320 days (IQR,
179–365); p value <0.001) during the 12-month
follow-up, we observed the distribution of recurrences at
separate follow-up times, and noted that the incident
proportion of patients who developed the recurrence
versus those still at risk was lower in the HA+CS group in
the latest part of follow-up, after 8 months (table 3). All
patients were alive at the 12-month follow-up. There
were 14 all-cause hospitalisations in the HA+CS group
and 1 in the control group.
HRQoL and resources consumption
In a subset of patients, a measure of the HRQoL as mea-
sured through the SF-36 or EQ-5D 3 level questionnaires
Table 1 Baseline characteristics
Characteristics HA+CS (N=181) Standard care (N=95) p Value
Age—mean (SD) 55.24 (17.33) 48.84 (21.16) 0.017
Employed—n (%) 83 (46) 62 (65) 0.003
Partner—n (%) 148 (82) 72 (76) 0.172
Sexually active—n (%) 114 (63) 60 (63) 0.931
Menopause—n (%) 69 (28) 49 (51) 0.038
BMI—mean (SD) 26.20 (6.37) 24.56 (5.03) 0.019
Postcoital infections—n (%) 31 (17) 29 (31) 0.012
Dyspareunia—n (%) 40 (22) 5 (5) <0.001
Severity RUTI—median (IQR)* 4 (2–5) 4 (3–4) 0.316
Prophylaxis—n (%)
Antimicrobial prophylaxis continuous NA 42 (44.21)
Antimicrobial prophylaxis postcoital NA 19 (20)
Intermittent immunoactive prophylaxis NA 28 (29.47)
On demand immunoactive therapy NA 1 (1.05)
Others NA 5 (5.26)
FSFI—mean (SD) 5.35 (8.71) 3.13 (5.43) 0.018
EQ-5D—median (IQR) 0.69 (0.24–0.73)† 0.69 (0.28–0.81)‡ 0.696
SF-36 PCS—median (IQR) 60 (54.5–70)§ 60 (53–67.5)¶ 0.500
SF-36 MCS—median (IQR) 60 (54–70)** 60 (53–67.5)¶ 0.551
*According to the European Association of Urology Guidelines on Urological Infections where 1 is low severity cystitis and 6 is extreme






BMI, body mass index; EQ-5D, Euro QoL 5D 3 level; FSFI, Female Sexual Function Index; HA+CS, hyaluronic acid and chondroitin sulfate;
NA, not applicable; RUTI, recurrent urinary tract infection; SF-36 MCS, Short Form 36 mental component score; SF-36 PCS, Short Form 36
physical component score.
Table 2 Bacteriologically confirmed recurrence, total number of recurrences and time to first recurrence between HA+CS
versus standard of care treated patients
Outcome OR (95% CI) Adjusted* OR (95% CI)
Bacteriologically confirmed recurrence 0.77 (0.46 to 1.28) 0.51 (0.27 to 0.96)
IRR (95% CI) Adjusted* IRR (95% CI)
Total number of bacteriologically confirmed recurrence 1.73 (1.27 to 2.37) 0.99 (0.69 to 1.43)
HR (95% CI) Adjusted* HR (95% CI)
Time to first bacteriologically confirmed recurrence 1.66 (1.09 to 2.54)† 0.99 (0.61 to 1.61)
*Adjusted for age, BMI, employment and menopause status, postcoital infections, dyspareunia, FSFI and severity of RUTI.
†Log-rank test p value 0.018.
BMI, body mass index; FSFI, Female Sexual Function Index; HA+CS, hyaluronic acid and chondroitin sulfate; IRR, incidence rate ratio; RUTI,
recurrent urinary tract infection.
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was available at baseline and after 12 months of
follow-up. There was no evidence of better improvement
in HRQoL in the HA+CS group compared with control
with SF-36 results, whereas when EQ-5D data were con-
sidered, the HA+CS group seemed to have received a
higher beneﬁt in terms of HRQoL than the control (see
online supplementary table S1).
There is a general reduction in physical units of
health resources (ie, medical visits, laboratory and
imaging tests) consumed by the two groups before the
treatment and during the follow-up (see online supple-
mentary table S2) without signiﬁcant differences
between the two groups.
Sensitivity analyses
We repeated all primary analyses and considered differ-
ent exposure intensity (ie, number of intravesical admin-
istrations received) in the HA+CS group. All ﬁndings
consistently show the additional beneﬁt gained by
patients when the number of instillations increases, pos-
sibly revealing the importance of adherence to this
medical device therapy for the treatment of RUTIs
(table 4). As a post hoc subgroup analysis, we repeated
primary analyses in non-sexually active patients only and
obtained similar patterns of results as in the whole
sample, although with loss of statistical signiﬁcance.
DISCUSSION
In this European multicentre retrospective observational
study, we compared bacteriologically conﬁrmed recur-
rence rates at the 12 month follow-up after the initiation
of intravesical administration of HA+CS versus standard
of care for the treatment of RUTIs. After adjusting for
unbalanced confounding factors between the two
groups, we observed that the HA+CS patients had a 49%
reduction (OR 0.51, 95% CI 0.27 to 0.96) in the risk of
a bacteriologically conﬁrmed recurrence, whereas there
was no statistical evidence for a difference in the inci-
dence and hazard rates of such recurrences between the
two groups.
Four clinical studies28–31 have been performed to
investigate the efﬁcacy and tolerability of intravesically
administered GAG for RUTI prophylaxis, all showing
that HA alone or HA+CS instillations reduce the
number of UTIs per patient per year at no increased
risk of severe adverse events and prolong the time inter-
val between RUTI episodes, with a high rate of patients
being free of recurrence at the end of the study period.
In particular, two randomised control trials (RCTs)
studies compared HA+CS administration to either
placebo29 or long-term antibiotic prophylaxis using sulfa-
methoxazole 200 mg and trimethoprim 40 mg.30
Damiano et al report a decrease in the UTI rate per
patient of 77% (95% CI 72.3 to 80.8) in the experimen-
tal versus placebo group, whereas De Vita and collea-
gues report the mean±SD number of recurrent cystitis
per patient per year as 1±1.2 vs 2.3±1.4 in HA+CS and
antibiotic treated patients, respectively. Despite the pro-
spective and randomised design, these trials were
limited by the small sample size (ie, they included 57
and 28 patients, respectively) and the single centre
setting that considerably reduces the generalisability of
Table 3 Incidence of bacteriologically confirmed












0–90 15.3 12.7 0.610
91–180 15.6 12.9 0.628
181–240 10.7 3.7 0.132
241–365 16.3 30.8 0.043
HA+CS, hyaluronic acid and chondroitin sulfate.
Table 4 Sensitivity analysis—impact of number of intravesical administration of HA+CS on clinical outcomes
Bacteriologically confirmed recurrence OR (95% CI) Adjusted* OR (95% CI)
≥5 Instillations (n=156) vs standard of care 0.81 (0.48 to 1.36) 0.52 (0.27 to 0.99)
≥6 Instillations (n=134) vs standard of care 0.69 (0.40 to 1.18) 0.47 (0.25 to 0.91)
≥7 Instillations (n=82) vs standard of care 0.63 (0.34 to 1.14) 0.43 (0.21 to 0.88)
Total number of bacteriologically confirmed recurrence IRR (95% CI) Adjusted* IRR (95% CI)
≥5 Instillations vs standard of care 1.82 (1.33 to 2.49) 1.05 (0.73 to 1.52)
≥6 Instillations vs standard of care 1.64 (1.18 to 2.28) 0.97 (0.66 to 1.40)
≥7 Instillations vs standard of care 1.46 (1 to 2.13) 0.90 (0.60 to 1.36)
Time to first bacteriologically confirmed recurrence HR (95% CI) Adjusted* HR (95% CI)
≥5 Instillations vs standard of care 1.72 (1.12 to 2.65) 1.04 (0.64 to 1.71)
≥6 Instillations vs standard of care 1.55 (0.99 to 2.41) 0.96 (0.58 to 1.57)
≥7 Instillations vs standard of care 1.33 (0.79 to 2.22) 0.85 (0.49 to 1.47)
*Adjusted for age, BMI, employment and menopause status, postcoital infections, dyspareunia, FSFI and severity of RUTI.
BMI, body mass index; FSFI, Female Sexual Function Index; HA+CS, hyaluronic acid and chondroitin sulfate; IRR, incidence rate ratio; RUTI,
recurrent urinary tract infection.
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the ﬁndings. While waiting for deﬁnitive RCT evidence
clarifying the comparative effectiveness proﬁle of this
therapy in support of its adoption, our observational
study design provides useful information around its
effectiveness in real-world practice.
In this respect, our study involved seven centres across
three European countries and 276 patients, thus provid-
ing important additional evidence with respect to
current treatment options for RUTIs. Furthermore, the
non-experimental observational design allows for a
closer representation of the routine clinical practice of
the use of the HA+CS reinstatement therapy as com-
pared with standard of care in place at high volume uni-
versity hospitals, that is on purpose deﬁned as very
broad given the variety of recommended strategies17 and
general scarce adherence to clinical guidelines.32
On the other hand, the retrospective design limited
the availability of data to that previously collected at the
centres. Contacting patients ex-post to gather additional
data was not applicable (eg, as in the case of HRQoL
assessment) or not helpful, given the potential signiﬁcant
recall bias introduced by delayed reporting. The issue of
missing data was dealt with by assuming that they were
missing at random (ie, given the observed data, data are
missing independently of unobserved data, ie, missing
data do not depend on the level of their outcome) and
applying pairwise deletion. In this regard, we performed
two additional analyses, ﬁrst by restricting the primary
analyses to all-complete-cases (ie, no missing values in
outcomes and adjusting variables) and providing similar
results to those presented here (data not shown).
Second, for all outcomes and adjusting variables, we
tested through Fisher’s exact test whether proportions of
missing values was different between HA+CS and
Standard of Care groups. No signiﬁcant difference was
observed with the exception of the resource consumption
where the number of missing values was higher in the
HA+CS group.
Data on uropathogens and AMR within the groups were
unfortunately not available from this database, although
we know that the most commonly prescribed antibiotics
were ciproﬂoxacin (13.2% of all prescriptions), cefurox-
ime (6.9%), fosfomycin (6.9%), nitrofurantoin (6.4%)
and E. coli bacterial extract (OM-89, 4.8%).
HRQoL assessment in routine practice is still uncom-
mon, as indicated by the signiﬁcant proportion of
missing information (up to 73% in the control group)
on this outcome. However, our ﬁndings are in line with
previous reports showing that the GAG replacement
treatment in women with RUTIs had a positive impact
on patients’ quality of life, reducing the symptoms and
improving the maximum cystometric capacity.29 30
RUTIs in women are a common condition, associated
with signiﬁcant morbidity and burden for the whole
society. In a study of 684 women aged 18–70 years with
UTI, participants reported an average of 3.83 symptom
days, 2.89 restricted-activity days, and 3.13 days during
which they were unwell.33 In another study, patients
reported 1.2 days on which they were not able to attend
classes or work, and 0.4 days in bed.34 New effective pre-
vention strategies are needed; in particular, non-
antimicrobial approaches would be desirable for several
reasons. First of all, a prolonged antibiotic use as a
prophylactic approach to RUTI increases the risk of side
effects, including vaginal and oral candidiasis, and
gastrointestinal symptoms.10 This, in turn, lowers
patients’ compliance and therefore the effectiveness of
the treatment.35 However, the most worrying effect of
the antibiotic use (and misuse) is the exacerbation of
AMR.36 Recently, a UK commissioned report on health
and macroeconomic consequences of AMR estimated 10
million extra deaths a year and costs up to €90 trillion
for the global economy by 2050 if this problem is not
tackled properly.37 Although this ﬁrst report might not
be as scientiﬁcally rigorous or informed by evidence as
possible,38 it brought renewed interest in the worldwide
AMR crisis. The war against the spread of drug-resistant
microbes is attracting considerable attention as well as
investment from all major governments and research
organisations in the EU and beyond.39 40 The way
forward outlined by all of these major research initiatives
includes establishing appropriate funding and rewards
to subsidise access to and development of new antibiotic
agents, preservation of existing drugs antimicrobial activ-
ity through prescription tailored to diagnosis, prioritisa-
tion and controlled access, and identiﬁcation of novel
approaches and therapies for microbial diseases.
The case of GAG reinstatement therapy is a good
example of an innovative approach to prevent and
manage bacterial urinary infections, a medical device
intervention as opposed to a drug. In contrast to anti-
biotic therapy, which aims at eradicating pathogens, treat-
ment with HA+CS targets bacterial adherence to the
bladder mucosa by physically recovering a damaged GAG
layer that facilitates bacterial adherence and, therefore,
RUTIs. Although patients who beneﬁt from the treat-
ment in the ﬁrst place might decide to undertake a
higher number of instillations compared with patients
who do not beneﬁt immediately, the different mechan-
ism of action could explain the apparent reduction in the
incidence of UTIs in the group treated with HA+CS instil-
lations compared with standard care when considering
later time intervals (table 3). While antibiotics are imme-
diately effective, although subject and conducive to resist-
ance, GAG layer administration is progressively restoring
the epithelium that will protect women from future uro-
pathogen infections. On the other hand, catheterisation-
induced UTIs might represent an unintended conse-
quence of this procedure. Previous reports29 30 have high-
lighted good tolerability and safety of the intervention
that must be performed under sterile conditions by
nurses trained in the procedure. As regards the economic
proﬁle of the two alternative approaches, it has been
reported that the cost of HA+CS could be even ﬁve times
higher than the cost for a 6-month antibiotic prophylaxis.
However, this consideration corresponds to a very
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restrictive, if not naïve, cost-analysis as it is well known
that all direct healthcare costs and consequences, includ-
ing those for the wider society, as would be containment
of drug-resistance spreading, should be taken into
account when assessing the cost-effectiveness proﬁles of
health technologies. Future methodologically sound eco-
nomic evaluation studies are recommended to compare
the societal or payer value of the two treatment strategies.
CONCLUSIONS
In order to treat and prevent RUTI, there is a need for
effective and safe alternative strategies for antimicrobial
therapy. Our study showed that in a real-world setting,
bladder instillation of combined HA+CS may reduce the
risk of bacteriologically conﬁrmed recurrences com-
pared with the current standard management in this
study population. Total incidence rates and hazard rates
were instead non-signiﬁcantly different between the two
groups. The number of HA+CS instillations seems to be
an important marker of success for intravesical administra-
tion therapy. Furthermore, in contrast to what happens
with antibiotic prophylaxis, owing to side effects and devel-
opment of resistance, the effectiveness of GAG reinstate-
ment therapy improves over time, with an even better
expected comparative effectiveness proﬁle in the long run.
Although ﬁrm conclusions are difﬁcult due to the
retrospective observational design, these ﬁndings high-
light the relevance of additional prospective and rando-
mised studies in this area and the promising role of the
HA+CS reinstatement therapy for prevention and treat-
ment of RUTI in an era of worryingly increased AMR.
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